Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter

Authors:

Abstract
Aim: We aimed to identify potent CpG signatures predicting temozolomide (TMZ) response in glioblastomas (GBMs) that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methyl... Plain language summary Glioblastomas that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of the MGMT gene (meMGMT) show considerable variability in t...
Funding Information
  • National Natural Science Foundation of China (81402049, 81802486)
  • Natural Science Foundation of Shandong Province (ZR2020QH0233)

This publication has 41 references indexed in Scilit: